Information Provided By: 
Fly News Breaks for August 15, 2019
ABEO
Aug 15, 2019 | 08:20 EDT
Maxim analyst Jason McCarthy downgraded Abeona Therapeutics to Hold from Buy without a price target. At the current burn rate and the Viital phase 3 study not expected to initiate until Q4, Abeona is likely going to need to raise capital, McCarthy tells investors in a research note. The analyst prefers to wait on the sidelines pending clarity on the RDEB trial and additional larger data sets from the Sanfilippo programs.
News For ABEO From the Last 2 Days
There are no results for your query ABEO
